000303217 001__ 303217
000303217 005__ 20250730114249.0
000303217 0247_ $$2doi$$a10.1093/ije/dyaf133
000303217 0247_ $$2pmid$$apmid:40714826
000303217 0247_ $$2pmc$$apmc:PMC12296387
000303217 0247_ $$2ISSN$$a0300-5771
000303217 0247_ $$2ISSN$$a1464-3685
000303217 037__ $$aDKFZ-2025-01568
000303217 041__ $$aEnglish
000303217 082__ $$a610
000303217 1001_ $$aLöfling, Leif Lukas$$b0
000303217 245__ $$aStatins and the risk of gynecological cancer: a Norwegian population-based cohort study.
000303217 260__ $$aOxford$$bOxford Univ. Press$$c2025
000303217 3367_ $$2DRIVER$$aarticle
000303217 3367_ $$2DataCite$$aOutput Types/Journal article
000303217 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1753794862_3434
000303217 3367_ $$2BibTeX$$aARTICLE
000303217 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303217 3367_ $$00$$2EndNote$$aJournal Article
000303217 500__ $$a#LA:C180# / Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
000303217 520__ $$aEndometrial, ovarian, and cervical cancers are the most common gynecological cancers, with 1.4 million diagnoses worldwide in 2022. Statins are widely used for cardiovascular conditions and have been studied for their association with gynecological cancer risk, but results to date have been inconclusive.We conducted a population-based cohort study including data from the Norwegian Prescription Database and the Cancer Registry of Norway, and followed women aged ≥50 years from 2004 to 2018. We examined the association between statin use overall and by type (lipophilic, hydrophilic), and the risk of endometrial, ovarian, and cervical cancers overall and by age groups and histologic subgroup using Cox proportional hazard models.The cohort study included 1 083 629 women. During a median follow-up of 11.6 years, 334 582 (31%) used statins at least once. There were 7709 cases of endometrial, 4415 cases of ovarian, and 1603 cases of cervical cancers. Statin use was associated with reduced risk of endometrial cancer [current use hazard ratio (HR) = 0.90, 95% confidence interval (CI): 0.85-0.96; past use HR = 0.79, 95% CI: 0.71-0.88]; associations were observed only for the lipophilic statins, and with similar associations by age groups and for type I and II endometrial cancer. No consistent associations were found for ovarian or cervical cancers. We found no trends for cumulative defined daily doses of current use or time since cessation for any cancer type.Statin use was associated with a reduced risk of endometrial cancer but not with the risk of ovarian cancer or cervical cancer.
000303217 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000303217 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303217 650_7 $$2Other$$acohort
000303217 650_7 $$2Other$$agynecological cancers
000303217 650_7 $$2Other$$apopulation-based
000303217 650_7 $$2Other$$arisk
000303217 650_7 $$2Other$$astatins
000303217 650_7 $$2NLM Chemicals$$aHydroxymethylglutaryl-CoA Reductase Inhibitors
000303217 650_2 $$2MeSH$$aHumans
000303217 650_2 $$2MeSH$$aFemale
000303217 650_2 $$2MeSH$$aNorway: epidemiology
000303217 650_2 $$2MeSH$$aHydroxymethylglutaryl-CoA Reductase Inhibitors: therapeutic use
000303217 650_2 $$2MeSH$$aMiddle Aged
000303217 650_2 $$2MeSH$$aAged
000303217 650_2 $$2MeSH$$aUterine Cervical Neoplasms: epidemiology
000303217 650_2 $$2MeSH$$aOvarian Neoplasms: epidemiology
000303217 650_2 $$2MeSH$$aOvarian Neoplasms: prevention & control
000303217 650_2 $$2MeSH$$aEndometrial Neoplasms: epidemiology
000303217 650_2 $$2MeSH$$aEndometrial Neoplasms: prevention & control
000303217 650_2 $$2MeSH$$aProportional Hazards Models
000303217 650_2 $$2MeSH$$aCohort Studies
000303217 650_2 $$2MeSH$$aRegistries
000303217 650_2 $$2MeSH$$aRisk Factors
000303217 650_2 $$2MeSH$$aGenital Neoplasms, Female: epidemiology
000303217 7001_ $$aStøer, Nathalie C$$b1
000303217 7001_ $$aBotteri, Edoardo$$b2
000303217 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b3$$eLast author$$udkfz
000303217 773__ $$0PERI:(DE-600)1494592-7$$a10.1093/ije/dyaf133$$gVol. 54, no. 4, p. dyaf133$$n4$$pdyaf133$$tInternational journal of epidemiology$$v54$$x0300-5771$$y2025
000303217 909CO $$ooai:inrepo02.dkfz.de:303217$$pVDB
000303217 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000303217 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000303217 9141_ $$y2025
000303217 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-20$$wger
000303217 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J EPIDEMIOL : 2022$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000303217 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J EPIDEMIOL : 2022$$d2024-12-20
000303217 9202_ $$0I:(DE-He78)C180-20160331$$kC180$$lKrebsepidemiologie$$x0
000303217 9201_ $$0I:(DE-He78)C180-20160331$$kC180$$lKrebsepidemiologie$$x0
000303217 980__ $$ajournal
000303217 980__ $$aVDB
000303217 980__ $$aI:(DE-He78)C180-20160331
000303217 980__ $$aUNRESTRICTED